In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.
Magazine
We are pleased to inform you about our first #webinar sessions❗ On October 30th we talked about #UTIPROPLUS and its use in uncomplicated #UTIs.
Urinary tract infections account for the third most common type of infectious pathology after respiratory and gastrointestinal processes. The agent responsible for such urinary tract infections is in most cases the bacterium Escherichia coli that migrates from the intestine and invades the urinary tract.
In a recent publication in Microbial Physiology, Dr Emanuela Esposito, of the University of Messina, under the direction of Professor Salvatore Cuzzocrea, has seen in a study conducted in rats infected with E coli as their intestinal and urinary bacterial load is significantly reduced when they are previously treated with xyloglucan alone or with xyloglucan combined with gelose. Similarly, histological lesions in the intestinal and urinary wall resulting from infection are reduced. It is thus confirmed that these polymeric substances create a physical barrier that reduces intestinal reservoirs of pathogenic bacteria supporting their beneficial role in the treatment and prevention of urinary tract infections. The marketed products containing these substances in their composition can thus see their totally innovative mode of action fully explained.
Despite the high prevalence of UTIs in the elderly, treatment options are limited. Although the medical community may agree in principle about the need for rational antibiotic usage, the absence of effective alternatives to treat UTIs can be a genuine barrier to change. Elderly patients are not only more prone to UTIs but are also more likely to have comorbidities and require multiple medications. The option to use a device that acts in a physical manner (barrier effect) without pharmacological properties, and with potential to reduce antimicrobial use, has obvious appeal in this patient population.